Atossa Therapeutics Stock Price

0.09 (6.38%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,716,675
Bid Price 1.47
Ask Price 1.50
News -
Day High 1.48


52 Week Range


Day Low 1.38
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Atossa Therapeutics Inc ATOS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 6.38% 1.50 19:10:47
Open Price Low Price High Price Close Price Prev Close
1.39 1.38 1.48 1.46 1.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,836 1,716,675 $ 1.43 $ 2,458,048 - 1.13 - 9.80
Last Trade Time Type Quantity Stock Price Currency
19:35:38 10 $ 1.50 USD


Draw Mode:

Atossa Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 189.94M 126.62M 126.57M $ - $ - -1.97 -1.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 0.40%

more financials information »

Atossa Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATOS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.561.621.381.491,854,152-0.06-3.85%
1 Month1.901.971.381.682,888,875-0.40-21.05%
3 Months2.78882.9081.382.173,119,429-1.29-46.21%
6 Months6.807.151.383.395,971,525-5.30-77.94%
1 Year1.20669.801.133.7613,323,0920.293424.32%
3 Years1.429.800.7553.575,313,6810.085.63%
5 Years18.0022.200.7554.143,825,383-16.50-91.67%

Atossa Therapeutics Description

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Your Recent History
Atossa The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.